Literature DB >> 19262496

Inhibition of the renin-angiotensin system and target organ protection.

Jun Iwanami1, Masaki Mogi, Masaru Iwai, Masatsugu Horiuchi.   

Abstract

The renin-angiotensin system (RAS) is involved in the pathological mechanisms of target organ damage, as well as in the induction of hypertension. RAS inhibition by angiotensin converting enzyme (ACE) inhibitors and angiotensin (Ang) II receptor blockers can prevent tissue damage by inhibition of Ang II type 1 receptor signaling. A beneficial effect of RAS inhibition on the heart, vasculature and kidney in cardiovascular disease has been reported. However, RAS inhibition can also prevent fibroproliferative diseases and damage of other tissues, such as brain, adipose tissue and muscle, because local RAS has an important role in tissue damage compared with circulating RAS. Moreover, other players, such as Ang II type 2 receptor signaling, aldosterone and ACE2 have been highlighted. Furthermore, there has also been a focus on the emerging concept of regulation of RAS, such as receptor-interacting proteins and receptor modifications, in the new discovery of therapeutic agents for tissue protection. The RAS has a pivotal role in various target organ damage, with complicated mechanisms; therefore, blockade of RAS may be therapeutically effective in preventing organ damage, as well as in having an antihypertensive effect.

Entities:  

Mesh:

Year:  2009        PMID: 19262496     DOI: 10.1038/hr.2009.5

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  16 in total

Review 1.  Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.

Authors:  Lakshmi Pulakat; Vincent G DeMarco; Sivakumar Ardhanari; Anand Chockalingam; Rukhsana Gul; Adam Whaley-Connell; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-03       Impact factor: 3.619

2.  Reversal of deleterious effect of hypertension on the liver by inhibition of endoplasmic reticulum stress.

Authors:  Nur Banu Bal; Sevtap Han; Saba Kiremitci; Mecit Orhan Uludag; Emine Demirel-Yilmaz
Journal:  Mol Biol Rep       Date:  2020-02-19       Impact factor: 2.316

Review 3.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

4.  Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension.

Authors:  Baojian Xue; Terry G Beltz; Yang Yu; Fang Guo; Celso E Gomez-Sanchez; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-26       Impact factor: 4.733

Review 5.  Programming of Essential Hypertension: What Pediatric Cardiologists Need to Know.

Authors:  Joana Morgado; Bruno Sanches; Rui Anjos; Constança Coelho
Journal:  Pediatr Cardiol       Date:  2015-05-27       Impact factor: 1.655

6.  Activation of the ACE2/Ang-(1-7)/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction.

Authors:  J Zheng; G Li; S Chen; J Bihl; J Buck; Y Zhu; H Xia; E Lazartigues; Y Chen; J E Olson
Journal:  Neuroscience       Date:  2014-05-09       Impact factor: 3.590

7.  Oxidative stress in the brain causes hypertension via sympathoexcitation.

Authors:  Takuya Kishi; Yoshitaka Hirooka
Journal:  Front Physiol       Date:  2012-08-17       Impact factor: 4.566

8.  Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases.

Authors:  Yuko Takahashi; Shiori Haga; Yukihito Ishizaka; Akio Mimori
Journal:  Arthritis Res Ther       Date:  2010-05-14       Impact factor: 5.156

Review 9.  Cardiac insulin resistance and microRNA modulators.

Authors:  Lakshmi Pulakat; Annayya R Aroor; Rukhsana Gul; James R Sowers
Journal:  Exp Diabetes Res       Date:  2011-07-31

10.  Roles of Brain Angiotensin II in Cognitive Function and Dementia.

Authors:  Masaki Mogi; Jun Iwanami; Masatsugu Horiuchi
Journal:  Int J Hypertens       Date:  2012-12-11       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.